Indian Society20 November 20263 min read
WHO report records 38% fall in India’s TB mortality as 2025 target is missed
The World Health Organization (WHO) released its Global Tuberculosis Report 2026 in November 2026. It reported that India’s TB mortality fell 38% since 2015, but the country missed its 2025 elimination target.
India’s annual TB deaths were estimated at 2.63 lakh in 2025, down from over 3 lakh in 2024. The country continued to account for about a quarter of estimated global incident cases.
India’s TB deaths fell, while case numbers remain high
India’s mortality rate fell faster than the global average between 2015 and 2025.
| Measure | India | Global comparison |
|---|---|---|
| TB mortality rate | 28 per lakh in 2015; 18 per lakh in 2025 | 35% decline, compared with India’s 38% |
| Estimated annual TB deaths | 2.63 lakh in 2025, down from over 3 lakh in 2024 | 23% of 1.13 million global TB deaths |
| Notified TB cases | 25.3 lakh in 2025, down from 26.18 lakh in 2024 | India accounts for about 25% of 10.6 million estimated incident cases |
| Treatment success for drug-susceptible TB | 94% under the National TB Elimination Programme (NTEP) | Not given |
India remains on all three WHO high-burden country lists, covering TB, TB/HIV and multidrug-resistant/rifampicin-resistant TB (MDR/RR-TB).
India’s 2025 targets were higher than WHO’s global targets
The National Strategic Plan for TB Elimination (2017–2025) set targets against 2015 levels. India aimed to reduce incidence by 80% and mortality by 90% by 2025, but missed its national target.
The WHO End TB Strategy set lower global milestones for 2025, followed by more ambitious targets for 2030.
| Framework | Target year | Reduction in incidence from 2015 | Reduction in deaths from 2015 |
|---|---|---|---|
| National Strategic Plan for TB Elimination | 2025 | 80% | 90% |
| WHO End TB Strategy | 2025 | 50% | 75% |
| WHO End TB Strategy | 2030 | 80% | 90% |
Gaps in diagnosis and social conditions impede progress
The report identifies barriers across diagnosis, treatment continuity and living conditions:
- Diagnosis and private-sector care: Access to testing is uneven in remote areas, and delayed diagnosis can leave cases undetected. Incomplete notification and gaps in treatment continuity in the private healthcare sector also pose challenges.
- Socio-economic conditions: Undernutrition, crowded housing and poor ventilation add to the burden. Patients may face travel, nutrition and lost-wage costs even when public-sector medicines are free.
- Drug-resistant TB: MDR/RR-TB requires complex drug-susceptibility testing, and identifying resistant cases and linking them to care remain difficult. Six-month, all-oral BPaLM regimens have eased treatment for eligible patients.
Clinical complexity and other illnesses complicate TB care
Extrapulmonary TB, which can affect the lymph nodes, bones, spine and abdomen, can be difficult to diagnose. Paediatric TB also presents diagnostic challenges, including difficulty collecting sputum samples from children.
The BCG vaccine helps protect young children against severe forms of TB, such as TB meningitis, but does not provide complete protection. HIV, diabetes and undernutrition can worsen outcomes, while some TB survivors face lasting lung damage.
WHO is reviewing India’s TB incidence estimate
WHO withheld India’s estimated TB incidence for 2025 while it assesses District-level sentinel surveillance data collected during 2025 from 50 representative districts.
The revised estimate is expected in early 2027, after the surveillance data are assessed alongside the 2020–21 National TB Prevalence Survey.